CHITOZAN AS AN ADJUVANT FOR INACTIVATED VACCINES AGAINST AVIAN INFLUENZA VIRUSES


Cite item

Full Text

Abstract

Aim. To study chitozan as an adjuvant for inactivated vaccines against A/H5 influenza viruses. Materials and methods. Avian A/H5 influenza viruses were grown on chicken embryos or on MDCK cell line; viruses-containing fluid was inactivated with formalin. Mice were vaccinated intramuscularly with inactivated avian influenza virus mixed with chitozan and then levels of hemagglutination-inhibiting and neutralizing antibodies as well as protective efficacy against both homologous and drifted strains of avian influenza viruses A/H5 were measured. Results. Addition of chitozan to inactivated preparations of A/H5 avian influenza viruses for immunization of mice significantly increased levels of hemagglutination-inhibiting and neutralizing antibodies to both homologous and drifted variants of A/H5 influenza viruses, including those containing neuraminidase from other subtype as well as strains isolated 10 — 20 years earlier than virus used for vaccination. Chitozan significantly improved protective efficacy of inactivated avian influenza vaccines against infection with both homologous and drifted variant of the virus. Vaccination with inactivated avian influenza viruses A/H5 and chitozan induced high levels of antibodies even after single immunization as well as after administration of 8-fold reduced dose of preparation. Conclusion. Chitozan is a perspective adjuvant for inactivated vaccines against avian influenza viruses, which could significantly improve immune response and protective efficacy against both homologous and drifted variants of avian influenza viruses A/H5.

Full Text

ХИТОЗАН КАК АДЪЮВАНТ ДЛЯ ИНАКТИВИРОВАННЫХ ВАКЦИН ПРОТИВ ВИРУСОВ ГРИППА ПТИЦ
×

About the authors

Yu. Z Ghendon

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

Yu. M Vasilyev

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

S. G Markushin

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

I. I Akopova

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

I. B Koptyaeva

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

G. G Krivtsov

Mechnikov Research Institute of Vaccines and Sera; Sechenov Moscow Medical Academy, Moscow, Russia

References

  1. Бурцева Е.И., Слепушкин А.Н., Власова Л.Н. и др. Опыт вакцинопрофилактики гриппа у лиц пожилого возраста. Реактогенность и иммуногенность инактивированных гриппозных вакцин. Журн. микробиол. 2000, 5: 42—45.
  2. Aguilar J., Rodriguez E. Vaccine adjuvants revisited. Vaccine. 2007, 25: 3752—3762.
  3. Bernstein D., Edwards K., Dekker C. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 2008, 197: 667—675.
  4. Bresson J., Perronne C., Launay O. et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006, 367: 1657—1664.
  5. CDC. Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine. Morb. Mortal. Wkly. Rep.2004, 53: 8—11.
  6. Del Giudice G., Hilbert A., Bugarini R. et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006, 24: 3063—3065.
  7. Ghendon Yu.Z., Markushin S., Akopova I. et al. Development of cell culture (MDCK) live coldadapted (CA) attenuated influenza vaccine. Ibid. 2005, 23: 4678—4684.
  8. Ghendon Yu.Z., Markushin S., Krivtsov G. et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch. Virol. 2008, 153: 831—837.
  9. Hasegawa H., Ichinohe T., Strong P. et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J. Med. Virol. 2005, 75: 130—136.
  10. Leroux-Roels I., Borkowski A., Vanwolleghem T. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007, 370: 580—589.
  11. Lin J., Zhang J., Dong X. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Ibid. 2006, 368: 991—997.
  12. Maeda T., Shintani Y., Nakano K. et al. Failure of inactivated influenza A vaccine to protect healthy children aged 6—24 months. Pediatr. Int. 2004, 46: 122—125.
  13. Mutsch M., Zhou W., Rhodes P. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New Engl. J. Med. 2004, 350: 896—903.
  14. Strong P., Clark H., Reid K. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin. Exp. Allergy. 2002, 32: 1794—1800.
  15. Vu T., Farish S., Jenkins M. et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002, 20: 1831—1836.
  16. Wood J., Robertson J. Development of a vaccine for humans against highly pathogenic avian influenza virus. Euro Surveillance. 2004, 9: 31—32.
  17. Zaharoff D., Rogers C., Hance K. et al. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007, 25: 2085—2094.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Ghendon Y.Z., Vasilyev Y.M., Markushin S.G., Akopova I.I., Koptyaeva I.B., Krivtsov G.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies